Literature DB >> 12139373

Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort.

Y Molad1, A Gorshtein, A J Wysenbeek, D Guedj, R Majadla, A Weinberger, M Amit-Vazina.   

Abstract

Systemic lupus erythematosus-associated irreversible organ/system damage was previously associated with various clinical and demographic features. We analysed the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI) in a cohort of 151 Israeli patients followed for a mean (+/- s.d.) period of 45.7 +/- 37.4 months. Mean score of SLICC/ACR DI at the first and last encounters were 0.17 +/- 64 and 1.64 +/- 2.1, respectively (P < 0.0001). Multiple logistic regression analyses disclosed a statistically significant positive correlation with corticosteroid and cyclophosphamide therapy. Hydroxychloroquine therapy was significantly associated with lower SLICC/ACR DI. Although the size of our study group did not allow us to find specific organs/systems which were associated with the protective effect of hydroxychloroquine, we suggest this is due to the antiatherogenic effects attributed to antimalarial therapy in SLE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12139373     DOI: 10.1191/0961203302lu203ra

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  30 in total

Review 1.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

2.  Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.

Authors:  Xiao-Xuan Wu; Seth Guller; Jacob H Rand
Journal:  Am J Obstet Gynecol       Date:  2011-06-24       Impact factor: 8.661

3.  Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome.

Authors:  Entela Nuri; Mara Taraborelli; Laura Andreoli; Marta Tonello; Maria Gerosa; Antonia Calligaro; Lorenza Maria Argolini; Rajesh Kumar; Vittorio Pengo; Pier Luigi Meroni; Amelia Ruffatti; Angela Tincani
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 4.  New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.

Authors:  Daniel J Wallace; Vineet S Gudsoorkar; Michael H Weisman; Swamy R Venuturupalli
Journal:  Nat Rev Rheumatol       Date:  2012-07-17       Impact factor: 20.543

Review 5.  Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article.

Authors:  Annamaria Mascolo; Pasquale Maria Berrino; Pietro Gareri; Alberto Castagna; Annalisa Capuano; Ciro Manzo; Liberato Berrino
Journal:  Inflammopharmacology       Date:  2018-06-09       Impact factor: 4.473

6.  Organ damage in patients with incomplete lupus syndromes: from a Chinese academic center.

Authors:  Zhen Chen; Meng-Tao Li; Dong Xu; Xiao-Mei Leng; Qian Wang; Xin-Ping Tian; Shang-Zhu Zhang; Yan Zhao; Xiao-Feng Zeng
Journal:  Clin Rheumatol       Date:  2015-02-18       Impact factor: 2.980

Review 7.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

8.  Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.

Authors:  Tünde Tarr; Gábor Papp; Nikolett Nagy; Edina Cserép; Margit Zeher
Journal:  Clin Rheumatol       Date:  2016-11-26       Impact factor: 2.980

9.  Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Anthony W Ashton; Pojen P Chen; James J Hathcock; Harry A M Andree; Douglas J Taatjes
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

10.  Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Pojen P Chen; James J Hathcock; Douglas J Taatjes
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.